Genmab A/S (GMAB)

業務介紹

Genmab A/S是一家位於丹麥的公司，專注於開發用於治療癌症和其他疾病的抗體治療方法。該公司推出了DARZALEX，一種用於治療多發性骨髓瘤（MM）患者的人源單克隆抗體；teprotumumab，用於治療甲狀腺眼病；ofatumurnab，一種用於治療慢性淋巴細胞白血病（CLL）和多發性硬化症的人源單克隆抗體；以及Amivantamab，用於治療晚期或轉移性胃食道癌和非小細胞肺癌（NSCLC）。其產品包括daratumumab，用於治療MM、非MM血液癌症和AL淀粉樣變性；GEN1047；tisotumab vedotin，用於治療宮頸癌、卵巢癌和實體腫瘤；DuoBody-PD-L1x4-1BB和DuoBody-CD40x4-1BB，用於治療實體腫瘤；Epcoritamab，用於治療復發/難治性弥漫性大B細胞淋巴瘤和慢性淋巴細胞白血病；以及HexaBody-CD38和DuoHexaBody-CD37，用於治療血液恶性腫瘤。該公司還正在進行第2階段的產品開發，其中包括Teclistamab，用於治療血管阻塞危機；Camidanlumab tesirine，用於治療霍奇金淋巴瘤和實體腫瘤；JNJ-64007957和JNJ-64407564，用於治療MM；PRV-015，用於治療腹腸疾病；Mim8，用於治療血友病A；以及Lu AF82422，用於治療多系統萎縮症。此外，該公司還與Seagen Inc.簽訂了商業許可和合作協議，共同開發tisotumab vedotin；與CureVac AG簽訂了合作協議，進行基於差異化mRNA的抗體產品的研究和開發；與AbbVie合作開發epcoritamab；並與BioNTech、Janssen、Novo Nordisk A/S、BliNK Biomedical SAS和Bolt Biotherapeutics, Inc.等公司進行合作。Genmab A/S成立於1999年，總部位於丹麥哥本哈根。

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

公司網址

https://www.genmab.com